Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610
- 1 April 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (7) , 1238-1248
- https://doi.org/10.1200/jco.2003.02.025
Abstract
Purpose: DNA ploidy has consistently been found to be a correlate of prostate cancer patient outcome. However, a minority of studies have used pretreatment diagnostic material and have involved radiotherapy (RT)-treated patients. In this retrospective study, the predictive value of DNA ploidy was evaluated in patients entered into Radiation Therapy Oncology Group protocol 8610. The protocol treatment randomization was RT alone versus RT plus short-course (∼4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB). Patients and Methods: The study population consisted of 149 patients, of whom 74 received RT alone and 75 received RT+TAB. DNA content was determined by image analysis of Feulgen stained tissue sections; 94 patients were diploid and 55 patients were nondiploid. Kaplan-Meier univariate survival, the cumulative incidence method, and Cox proportional hazards multivariate analyses were used to evaluate the relationship of DNA ploidy to distant metastasis and overall survival. Results: DNA nondiploidy was not associated with any of the other prognostic factors in univariate analyses. In Kaplan-Meier analyses, 5-year overall survival was 70% for those with diploid tumors and 42% for nondiploid tumors. Cox proportional hazards regression revealed that nondiploidy was independently associated with reduced overall survival. No correlation was observed between DNA ploidy and distant metastasis. The diminished survival in the absence of an increase in distant metastasis was related to a reduction in the effect of salvage androgen ablation; patients treated initially with RT+TAB and who had nondiploid tumors had reduced survival after salvage androgen ablation. Conclusions: Nondiploidy was associated with shorter survival, which seemed to be related to reduced response to salvage hormone therapy for those previously exposed to short-term TAB.Keywords
This publication has 41 references indexed in Scilit:
- CAN PLOIDY OF PROSTATE CARCINOMA DIAGNOSED ON NEEDLE BIOPSY PREDICT RADICAL PROSTATECTOMY STAGE AND GRADE?Journal of Urology, 1999
- DEOXYRIBONUCLEIC ACID PLOIDY AND SERUM PROSTATE SPECIFIC ANTIGEN PREDICT OUTCOME FOLLOWING SALVAGE PROSTATECTOMY FOR RADIATION REFRACTORY PROSTATE CANCERJournal of Urology, 1999
- Influence of dna ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomyUrology, 1995
- Original Articles: Prostate Cancer: Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 DiseaseJournal of Urology, 1995
- Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancerUrology, 1994
- On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology DataJournal of the American Statistical Association, 1993
- DNA‐ploidy as prognostic factor in prostatic carcinomaInternational Journal of Cancer, 1990
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcomeBritish Journal of Surgery, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958